Bioequivalence Study of Test and Reference 400 mg Ibuprofen Coated Tablets in Healthy Volunteers
Status:
Completed
Trial end date:
2022-05-31
Target enrollment:
Participant gender:
Summary
This study is a comparative bioavailability study performed to assess bioequivalence between
Test medicinal product (Darfen 400, 400 mg ibuprofen coated tablets [512 mg ibuprofen sodium
dihydrate], manufactured by PrJSC "Pharmaceutical firm "Darnitsa" [Ukraine]) and Reference
medicinal product (marketed medicinal product Nurofen® Forte Express, 400 mg ibuprofen coated
tablets [512 mg ibuprofen sodium dihydrate], manufactured by Reckitt Benckiser [Poland] S.A.)
in healthy volunteers.